LOS ANGELES, CA - (NewMediaWire) - January 18, 2024 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.

In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder ("ASD"), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD.

The study, a comprehensive 14-week randomized, double-blind, placebo-controlled trial, enrolled 52 boys aged 415 years with moderate to severe ASD. Focused on evaluating the efficacy and safety of suramin intravenous infusions, the study's 10 mg/kg suramin arm displayed promising results in improving

Read More

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

The latest news and updates relating to PXMD are available in the company's newsroom at https://ibn.fm/PXMD

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California

www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]